Xponance Inc. Has $566,000 Stock Holdings in Haemonetics Co. (NYSE:HAE)

Xponance Inc. lifted its stake in shares of Haemonetics Co. (NYSE:HAE) by 5.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,246 shares of the medical instruments supplier’s stock after buying an additional 404 shares during the period. Xponance Inc.’s holdings in Haemonetics were worth $566,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of HAE. Parkside Financial Bank & Trust grew its stake in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock worth $92,000 after buying an additional 240 shares in the last quarter. AlphaQuest LLC boosted its position in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after acquiring an additional 1,826 shares in the last quarter. KBC Group NV boosted its position in shares of Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after acquiring an additional 712 shares in the last quarter. iSAM Funds UK Ltd bought a new stake in Haemonetics during the third quarter worth $204,000. Finally, HighTower Advisors LLC grew its holdings in shares of Haemonetics by 7.8% during the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 244 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

HAE has been the subject of a number of recent research reports. Barrington Research decreased their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Bank of America downgraded Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $95.00 to $68.00 in a research report on Friday, February 7th. JMP Securities reduced their target price on Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a report on Friday, February 7th. Needham & Company LLC lowered their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, March 18th. Finally, Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Price Performance

Shares of NYSE HAE opened at $63.39 on Wednesday. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The firm’s 50-day moving average price is $66.66 and its 200-day moving average price is $74.89. The firm has a market capitalization of $3.18 billion, a P/E ratio of 24.96, a P/E/G ratio of 1.11 and a beta of 0.43. Haemonetics Co. has a 1-year low of $58.80 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. Equities research analysts anticipate that Haemonetics Co. will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.